A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Delpacibart etedesiran (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms MARINA
- Sponsors Avidity Biosciences
Most Recent Events
- 27 Feb 2025 According to an Avidity Biosciences media release, publication of data analyses from the completed Phase 1/2 MARINA trial in 2025.
- 08 Jan 2025 According to an Avidity Biosciences media release, the company is planned the presentation of additional data analyses from the study in 1Q of 2025.
- 07 Oct 2023 New positive AOC 1001 data from this trial presented in an Avidity Biosciences media release.